Ardizzoni A, Grossi F, Pennucci M C
Istituto Nazionale per la Ricerca sul Cancro, Division of Medical Oncology I, Genova, Italy.
Monaldi Arch Chest Dis. 1998 Apr;53(2):236-40.
Malignant pleural mesothelioma (MPM) is an uncommon malignancy characterized by a rapid clinical course. Few patients are possible candidates for radical surgery. According to most reviews, radiotherapy has a limited role in the treatment of MPM. The role of chemotherapy in the management of pleural mesothelioma still remains uncertain. The available data indicate that although 10-20% of patients are known to achieve on objective response to a number of chemotherapeutic agents, the impact on survival appears limited and improvement in the quality of life remains uncertain. The results of combination chemotherapy are comparable to those of single-agent chemotherapy and no major difference is detectable among the various combinations. Prospective phase II trials are recommended for the identification of new active treatments while large-scale randomized phase III trials are needed to identify the best available treatment. In addition, new standard criteria for eligibility and response assessment are required. This paper reviews the available literature on the systemic drug therapy of MPM.
恶性胸膜间皮瘤（MPM）是一种临床病程进展迅速的罕见恶性肿瘤。很少有患者适合进行根治性手术。根据大多数综述，放疗在MPM治疗中的作用有限。化疗在胸膜间皮瘤管理中的作用仍不明确。现有数据表明，虽然已知10%-20%的患者对多种化疗药物有客观反应，但对生存的影响似乎有限，生活质量的改善仍不确定。联合化疗的结果与单药化疗相当，不同联合方案之间未发现重大差异。建议进行前瞻性II期试验以确定新的有效治疗方法，同时需要大规模随机III期试验来确定最佳可用治疗方案。此外，还需要新的 eligibility 和反应评估标准。本文综述了MPM全身药物治疗的现有文献。 （注：原文中eligibility未给出准确中文释义，可根据语境理解为“入选标准”等类似意思 ）
